PeerCurrent.com|Stay current with the people and research shaping what comes next.

Your Feed AI Summary Saved Board Expert Discussion This Week in Your Field

Follows Journals Trials Guidelines Markets

Researcher

Laura Savage

Leeds Teaching Hospitals NHS Trust

1 development in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

For You Latest Breakthroughs Trials Reviews Guidelines

Latest

Everything in the corpus, newest first.

SEP 7, 2026 · JOURNAL ARTICLE

Real-world Drug Survival of Guselkumab in Patients With Psoriasis Stratified by Weight and Comorbidities: Retrospective, Observational Data From the British Association of Dermatologists Biologics and Immunomodulators Register

Clinical and Experimental Dermatology

Retrospective real-world registry analysis confirming sustained drug survival of guselkumab across weight, BMI, and comorbidity strata over 36 months, with consistent outcomes but limited by observational design and missing baseline data.

Important Confirmatory EvidenceDermatology and Skin Diseases Maria-Angeliki Gkini Bhavika Chauhan

Reported

Overall 36-month drug survival0.75

95% CI overall drug survival0.71–0.79

Drug survival <80 kg0.71

PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support